ClinicalTrials.gg
DrugBiological

Ramucirumab clinical trials

Also written LY3009806, IMC-1121B and Cyramza.

studies test it
109
open now
11
in phase 3
16
first study started
2005

How each study uses Ramucirumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Ramucirumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
21 Apr 2014 · CYRAMZA · BLA 125477 (FDA, Drugs@FDA)
European Union
19 Dec 2014 · Cyramza · EMEA/H/C/002829 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Ramucirumab
88
Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B
11
Monoclonal Antibody HGS-ETR2
9
Ramucirumab (IMC-1121B)
6
IMC-1121B (ramucirumab)
4

Brand

Cyramza
39

Development codes

LY3009806
63
IMC-1121B
50
1121B
1
BLA 125477
1

Studies by the year they started

108 studies that test it; most in 2015 (13); 1 more planned to start later

Studies that test Ramucirumab, by start year
YearStudies
20051
20061
20072
20084
20095
20109
20116
20125
20131
20143
201513
201610
20175
20185
201912
202010
20214
20233
20244
20253
20262

Who runs them

Industry 58 · Other 51

Eli Lilly and Company (53) · SWOG Cancer Research Network (5) · Washington University School of Medicine (4) · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (3) · Memorial Sloan Kettering Cancer Center (2) · Samsung Medical Center (2) · Yonsei University (2) · Abramson Cancer Center at Penn Medicine (1)

Often tested with

Tested in the same studies.

Paclitaxel (18) · Pembrolizumab (7) · Irinotecan (7) · Nivolumab (4) · Albumin-Bound Paclitaxel (4) · Carboplatin (3) · Trastuzumab (3) · Abemaciclib (3)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 4 phase 3 studies under way

Ramucirumab is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 6

Studies that test Ramucirumab.

Studies

Open first, then newest update. How each study uses Ramucirumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 109

See all 109 studies that test Ramucirumab →

Given beside what is tested · 45 — Ramucirumab is usual care or a partner of the new treatment

Showing 20 of 45.

As the comparator · 9 — what is tested is compared with Ramucirumab

Codes

What other systems call Ramucirumab · ClinicalTrials.gg INT006871

  • MeSH (NLM) D000096662RamucirumabConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) D99YVK4L0XRAMUCIRUMABConfirmed FDA, NLM, Wikidata
  • RxNorm 1535922Confirmed FDA, Wikidata
  • Wikidata Q7290345ramucirumabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C70792RamucirumabOne source FDA
  • DrugBank DB05578One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.